1. Home
  2. BRID vs GNLX Comparison

BRID vs GNLX Comparison

Compare BRID & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bridgford Foods Corporation

BRID

Bridgford Foods Corporation

N/A

Current Price

$7.64

Market Cap

72.8M

ML Signal

N/A

Logo Genelux Corporation

GNLX

Genelux Corporation

HOLD

Current Price

$4.29

Market Cap

202.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BRID
GNLX
Founded
1932
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
72.8M
202.4M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
BRID
GNLX
Price
$7.64
$4.29
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$19.75
AVG Volume (30 Days)
2.6K
140.0K
Earning Date
01-28-2026
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$227,364,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.24
$1.99
52 Week High
$10.83
$8.54

Technical Indicators

Market Signals
Indicator
BRID
GNLX
Relative Strength Index (RSI) 48.23 39.40
Support Level $7.31 $4.20
Resistance Level $7.82 $4.37
Average True Range (ATR) 0.24 0.25
MACD -0.04 0.06
Stochastic Oscillator 30.65 37.52

Price Performance

Historical Comparison
BRID
GNLX

About BRID Bridgford Foods Corporation

Bridgford Foods Corp manufactures, markets, and distributes frozen and snack food products in the United States. The business segments are; the processing and distribution of frozen products, and the processing and distribution of snack food products. Its product offerings include meat snacks, breads and rolls, biscuits, and ready-to-eat sandwiches among others. The company offers frozen food products to the foodservice and retail customers through wholesalers, cooperatives, and distributors; and snack food items to supermarkets, and mass merchandise and convenience retail stores through customer-owned distribution centers, as well as a direct store delivery network. A majority of the company's revenue is derived from the snack food products segment.

About GNLX Genelux Corporation

Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.

Share on Social Networks: